Literatur Review: Pengaruh Pemberian Terapi ACEI/ARB Terhadap Mortalitas dan Adverse Outcome pada Pasien COVID-19 Literature Review: Impact of ACEI/ARB Therapy on Mortalities and Adverse Outcame in Patients with Covid-19
Main Article Content
Abstract
Severe acute respiratory syndrome coronavirus 2 merupakan virus pembawa corona virus disease 2019, yang terkait dengan tingginya insiden disfungsi multiorgan dan kematian menginfeksi manusia bergantung pada angiotensin converting enzyme 2 (ACE2) sehingga keamanan penggunaan pengobatan yang bekerja untuk meningkatkan ekspresi reseptor ACE2 seperti ACEI/ARB masih diperlukan pembuktian. Literature review ini dilakukan untuk mengetahui pengaruh ACEI/ARB terhadap kejadian mortalitas dan adverse outcome pada pasien COVID-19. Penelitian menggunakan literatur dari database Scopus, PubMed dan Science Direct. Pencarian literatur dengan kata kunci COVID-19, ACEI/ARB, Antihipertensi, Mortality dan outcome. Hasil penyaringan literatur diperoleh 19 artikel studi yang masuk kriteria inklusi. Ulasan ini menunjukkan hasil yang beragam terkait pengaruh ACEI/ARB terhadap perburukan klinis pasien COVID-19. Namun berdasarkan sejumlah artikel sistematik review dan meta-analisis dengan jumlah sampel yang cukup besar menunjukkan penggunaan ACEI/ARB tidak terkait dengan mortalitas dan perburukan klinis pasien (tidak dikaitkan dengan resiko admisi ke ICU, resiko penggunaan ventilasi mekanis invasif maupun non-invasif, peningkatan resiko rawat inap, serta resiko terinfeksi virus COVID-19). Kesimpulan: Penggunaan ACEI/ARB tidak berhubungan dan tidak mempengaruhi mortalitas serta perburukan luaran klinis pasien COVID-19, penggunaan ACEI/ARB sebelum terinfeksi direkomendasikan untuk dilanjutkan pada pasien COVID-19 untuk efek perbaikan pada kondisi pasien.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All rights reserved. This publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording.
References
Alrashed, A. A. (2021). Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study. Journal of Infection and Public Health, 14(6), 726–733. https://doi.org/10.1016/j.jiph.2021.03.004,
An, J. (2021). COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system. International Journal of Cardiology: Hypertension, 9(Query date: 2023-11-18 20:56:05). https://doi.org/10.1016/j.ijchy.2021.100088
Baslilar, S., & Saylan, B. (2021). Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: Retrospective analysis of 435 patients. Annals of Saudi Medicine, 41(5), 268–273. https://doi.org/10.5144/0256-4947.2021.268.
Bauer, A. Z. (2021). Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study. Journal of Clinical Hypertension, 23(1), 21–27. https://doi.org/10.1111/jch.14101.
Choksi, T. T. (2021). Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers. American Journal of Nephrology, 52(3), 250–260. https://doi.org/10.1159/000515232.
Hakeam, H. A., Alsemari, M., Duhailib, Z. A., Ghonem, L., Alharbi, S. A., Almutairy, E., Sheraim, N. M. B., Alsalhi, M., Alhijji, A., AlQahtani, S., Khalid, M., & Barry, M. (2021). Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study. Journal of Cardiovascular Pharmacology and Therapeutics, 26(3), 244–252. https://doi.org/10.1177/1074248420976279.
Ivanov, D. (2023). The dynamics of hypertension and renal function in CKD and non-CKD patients affected with COVID-19 – final results of BIRCOV trial. European Journal of Clinical and Experimental Medicine, 21(2), 230–238. https://doi.org/10.15584/ejcem.2023.2.3.
Kabia, A. U. (2022). The effects of hypertension on the prognosis of coronavirus disease 2019: A systematic review and meta-analysis on the interactions with age and antihypertensive treatment. Journal of Hypertension, 40(12), 2323–2336. https://doi.org/10.1097/HJH.0000000000003266.
Li, M., Wang, Y., Ndiwane, N., Orner, M. B., Palacios, N., Mittler, B., Berlowitz, D., Kazis, L. E., & Xia, W. (2021). The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension. PloS One, 16(3). https://doi.org/10.1371/journal.pone.0248652.
Ma, Y. (2021). Sex Differences in Association Between Anti-Hypertensive Medications and Risk of COVID-19 in Middle-Aged and Older Adults. Drugs and Aging, 38(10), 921–930. https://doi.org/10.1007/s40266-021-00886-y.
Ma, Z. (2021). Does taking an angiotensin inhibitor increase the risk for COVID-19? – A systematic review and meta-analysis. Aging, 13(8), 10853–10865. https://doi.org/10.18632/aging.202902.
Negreira-Caamaño, M. (2020). Impact of Treatment with Renin–Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19. High Blood Pressure and Cardiovascular Prevention, 27(6), 561–568. https://doi.org/10.1007/s40292-020-00409-7.
Oflar, E. (2022). The Effect of Renin-Angiotensin Blockers on COVID-19 Related Mortality: A Tertiary Center’s Experience. Cor et Vasa, 64(3), 277–281. https://doi.org/10.33678/cor.2021.123.
Pranata, R. (2020). The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14(5), 983–990. https://doi.org/10.1016/j.dsx.2020.06.047.
Safizadeh, F. (2022). Association of renin–angiotensin–aldosterone system inhibition with Covid-19 hospitalization and all-cause mortality in the UK biobank. British Journal of Clinical Pharmacology, 88(6), 2830–2842. https://doi.org/10.1111/bcp.15192.
Sharma, R., Kumar, A., Majeed, J., Thakur, A. K., & Aggarwal, G. (2022). Drugs acting on the renin-angiotensin-aldosterone system (RAAS) and deaths of COVID-19 patients: A systematic review and meta-analysis of observational studies. The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology, 74(1), 64. https://doi.org/10.1186/s43044-022-00303-8.
Tse, G. (2021). Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease. Journal of Hypertension, 39(8), 1717–1724. https://doi.org/10.1097/HJH.0000000000002866.
Xu, J., Huang, C., Fan, G., Liu, Z., Shang, L., Zhou, F., Wang, Y., Yu, J., Yang, L., Xie, K., Huang, Z., Huang, L., Gu, X., Li, H., Zhang, Y., Wang, Y., Hayden, F. G., Horby, P. W., Cao, B., & Wang, C. (2020). Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: A retrospective analysis. Frontiers of Medicine, 14(5), 601–612. https://doi.org/10.1007/s11684-020-0800-y.
Yin, J., Wang, C., Song, X., Li, X., & Miao, M. (2022). Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials. American Journal of Hypertension, 35(5), 462–469. https://doi.org/10.1093/ajh/hpac001.